Rose McNulty

Wojciech Jurczak, MD, PhD, head of the Department of Oncology at Maria Sklodowska-Curie National Research Institute of Oncology, discusses the changing therapy landscape for relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

The findings suggest that circulating N-terminal pro-B-type natriuretic peptide and growth differentiation factor-15, both soluble biomarkers of cardiovascular disease (CVD), may be indicators of the course of myelodysplastic syndromes (MDS) and outcomes.

Utilizing electronic patient-reported outcome measures (ePROMs) may hold potential to reduce health care resource utilization without affecting outcomes for patients with inflammatory arthritides, such as rheumatoid arthritis.

The occurrence of treatment-related myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) after autologous hematopoietic cell transplantation (HCT) for multiple myeloma was associated with aggressive disease characteristics and poor outcomes.

Patients with metastatic prostate cancer who face high financial toxicity resulting from treatment may cope in ways that impact overall quality of life, according to a recent study.

In a disease such as chronic myeloid leukemia (CML), shared treatment decision-making between providers and patients is key, said Fabian Lang, MD, of Goethe University Hospital in Frankfurt, Germany.

Ropeginterferon alfa-2b was moved to preferred status for patients with high- and low-risk polycythemia vera in a recent update to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology.

A predictive artificial intelligence (AI) biomarker of androgen deprivation therapy (ADT) benefit in prostate cancer was validated in a recent study published in NEJM Evidence.

The study aimed to assess whether CRF was associated with prostate, colon, and lung cancer incidence and mortality among men in Sweden.

Interpreting spirometry with race-specific reference equations led to a lower Lung Allocation Score (LAS) for Black patients and higher LAS among White patients, which could potentially contribute to racially biased allocation of lung transplants.

A panel of experts at the American Society of Clinical Oncology Annual Meeting presented the latest research and equity considerations for chimeric antigen receptor (CAR) T-cell therapy in hematological cancers.

A session chaired by ASCO and ESMO leadership included experts on the latest lung and colorectal cancer screening technologies and persistent disparities in screening access and uptake.

Talazoparib in combination with enzalutamide showed a 55% reduction in the risk of disease progression or death for patients with metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene mutations in the phase 3 TALAPRO-2 trial.

Initiating targeted therapy for eligible patients with advanced non–small cell lung cancer (NSCLC) was found to improve outcomes, even when patients were started on nontargeted therapy but switched in a timely manner.

There was no difference in second primary cancer risk among older adult male patients treated with intensity-modulated radiotherapy (IMRT) vs 3-dimensional conformal radiation therapy for prostate cancer.

Tycel Phillips, MD, hematologist-oncologist at City of Hope in Duarte, California, discusses the need for novel treatments for patients with diffuse large B-cell lymphoma (DLBCL).

A study presented at the American Society of Clinical Oncology Annual Meeting found practice- and provider-level racial and ethnic inequities in rates of next-generation sequencing (NGS) testing for patients with advanced non–small cell lung cancer (NSCLC) treated in the community setting.

Michael Thompson, president and CEO of the National Alliance of Healthcare Purchaser Coalitions, gave insight into the themes of the upcoming National Alliance Leadership Summits.

Tycel Phillips, MD, hematologist-oncologist at City of Hope in Duarte, CA, discussed the utility of epcoritamab in diffuse large B-cell lymphoma (DLBCL) and the potential impacts the bispecific antibody's recent approval will have in the community oncology setting.

An abstract at the American Society of Clinical Oncology Annual Meeting showed disparities in lung cancer screening rates in an urban, multiethnic community, and patient navigation increased rates overall.

The autologous CAR T-cell therapy axicabtagene ciloleucel (axi-cel) demonstrated effectiveness and safety consistent with the ZUMA-5 trial when used in real-world settings to treat a broader population of patients with follicular lymphoma (FL).

Much work is needed to address inequities and gaps in care access for patients with acute myeloid leukemia (AML), said Jeffrey Lancet, MD, chair of the Department of Malignant Hematology at Moffitt Cancer Center.

Barb Kunz, MS, LCGC, senior genetic counselor at the US Oncology Network, discussed the importance of germline genetic testing in patients with triple-negative breast cancer and other cancer types.

Research presented at the American Society of Clinical Oncology Annual Meeting found prostate-specific membrane antigen ligand positron emission tomography (PSMA-PET) to be associated with worse overall survival in prostate cancer without distant metastasis based on conventional imaging.

While efforts are underway to improve access to cutting-edge oncology clinical trials for underserved patients, more work is needed to get the job done, said a panel of experts at the 2023 American Society of Clinical Oncology Annual Meeting.

Jason Westin, MD, MS, FACP, director of the Lymphoma Clinical Research Program at the University of Texas MD Anderson Cancer Center, gave insight the ZUMA-7 trial of axicabtagene ciloleucel (axi-cel) in relapsed or refractory large B-cell lymphoma (R/R LBCL) and the study's implications in the broader LBCL landscape.

Barb Kunz, MS, LCGC, senior genetic counselor at the US Oncology Network, shared insight on a study of social determinants of health in the context of germline genetic testing for triple-negative breast cancer (TNBC) in the community oncology setting.

Roy S. Herbst, MD, PhD, deputy director of Yale Cancer Center and lead investigator for ADAURA, said the results erase any doubts about the use of osimertinib in early non–small cell lung cancer (NSCLC) for patients with EGFR mutations.